“Mikhail Blagosklonny:Rapamycin is the Fountain of Youth!”

Mikhail Blagosklonny is one of the foremost oncology experts waging war on cancer and the effects of growing old and his remarkable discoveries are regarded all over the world. The discovery of Rapamycin, which has shown to have notable healing properties and anti-aging compounds, has taken the world by storm and revolutionized the medical communities approach to treating disease and anti-aging. Mikhail developed the peer-reviewed medical journal, Oncotarget, to bridge the gap between doctors, patients and scientists in regard to disclosing all of the most relevant research findings and successful treatment methods available so that there are viable options to patients without having to rely on outside or hard to reach sources. Know more about Mikhail at Philly Purge.

Oncotarget was initially purposed exclusively to the discovery and publication of oncological research, but has grown so proficiently throughout the past 17 years that the medical journal now includes the areas of pathology, immunology, microbiology, autophagy, chromosome behavior, death cell cycle and other subjects. Oncotarget has become the go-to source for many medical doctors and practices when implementing a remedial treatment plan for disease. This is largely because the journal itself houses an extensive and innovative library of published research findings pertaining to disease cures and scientific lab studies that have been ongoing since its establishment in 2010.

Mikhail Blagosklonny’s work has been quite significant to a cancer cure breakthrough, a time-lapse or slowdown in the aging process and other cutting-edge scientific medical discoveries. His research with the drug Rapamycin has yielded great results for its antifungal properties and other incredible properties including helping the body to sustain organ transplants after surgeries. The origin of the drug Rapamycin was discovered from the Isle of Rapa Nui or Easter Island as it is commonly referred to. It was discovered approximately around the year 1987 and continued analysis of the drug has proven to suppress the progression of cancer cells, which is why it was cleared for treatment by the Food and Drug Administration.

View: http://healingmagic.net/2017/01/04/mikhail-blagosklonnys-plans-for-oncology/

Not only is Rapamycin used for oncological and anti-aging purposes, but when paired with other medical compounds it has shown to be effective for countering other maladies found in the body or in surgical conditions. For example, when Rapamycin is amalgamated with corticosteroids and cyclosporine, it has countered the effects of renal failure. Some of the most innovative medical treatment plans have shown successful results when using Rapamycin for the following therapies. Read more on templeofthecave.com.

  • Remedial therapy for treating Alzheimer’s disease which effects the degradation of the mind commonly found in aging people.
  • For a long lifespan due to its incredible anti-aging compounds.
  • Remedial use for treating Facial Fibroid cancer growths.
  • A cure for Tuberous Sclerosis Complex which are nonthreatening or dangerous tumors on various areas of the body.
  • Coronary Stent surgical procedures involving the application of overlay in the eyes.
  • Treatment of various forms of lung cancer.
  • Remedial cure for diseases of the blood system, which is commonly referred to as hemolytic-uremic condition.
  • Recent research has shown dying dogs have been revived through the administration of Rapamycin!

The Appointment of Clay Siegall to the Board of Mira Therapeutics

Mirna Therapeutics is a biotechnology-based firm. In January 2013, the company announced that Seattle Genetics would be appointed to the member of the board of council as an outside director. Clay Siegall is the co-founder of Seattle Genetics. He is the current chief executive and chairperson of the board of trustees of Seattle Genetics.

Mirna Therapeutics is based in Austin, Texas and was established in 2007. The firm focuses on microRNA in therapeutics. Currently, the company is focused on cancer research. Dr. Siegall has a background in cancer research, and that explains why he was appointed to the board of directors. Dr. Paul Lammers is the chief executive officer and president of Mira. Dr. Paul said that the company was excited to be associated with an expert who has experience in cancer research. Dr. Paul further explained that he expects Dr. Siegall to guide the company towards developing their microRNA-based therapeutics.

Mirna has a portfolio containing more than 300 miRNAs with applications in various diseases like oncology. It has foundational intellectual property collection on the therapeutic use of miRNAs. Oncology-directed miRNAs have proven to block the growth of tumor in different re-clinical animal studies. The firm has received funding from the state of Texas and private investors.

About Clay Siegall
Before founding Seattle Genetics, Dr. Siegall was working with Bristol-Myers Squibb Pharmaceutical Research Institute. He worked at the Institute from 1991 to 1997. Dr. Siegall also worked with the National Cancer Institute from 1988 to 1991 and National Institutes of Health. Dr. Siegall is on the board of directors of Alder BioPharmaceuticals, a private firm. He is also a member of the Council of Washington Biotechnology and Biomedical Association (WBBA). Dr. Siegall received a Ph.D. in Genetics from George Washington University. He also holds a B.S. in zoology from the University of Maryland.

Seattle Genetic is a biotechnology firm that deals with developing preclinical and clinical products. The biotech firm was formed in 1998. Over the years, the company has commercialized and developed innovative antibody-drug conjugate (ADC) for treating cancer. ADC is a technology that reduces toxic effects of chemotherapy and improves antitumor activity. The firm’s headquarters are in Bothell Washington. It trades on Nasdaq Stock Market.

Original Articles found below: